Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

被引:50
|
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Kwon, Mi [3 ]
Perez, Ariadna [4 ]
Parody, Rocio [5 ]
Ferra, Christelle [6 ]
Garcia Cadenas, Irene [1 ]
Herruzo, Beatriz [2 ]
Dorado, Nieves [3 ]
Hernani, Rafael [4 ]
Sanchez-Ortega, Isabel [5 ]
Torrent, Anna [6 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Gregorio Maranon, Hematol Dept, Madrid, Spain
[4] Hosp Clin Univ, Hematol Dept, Madrid, Spain
[5] Bellvitge Hosp, Hematol Dept, Barcelona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; RISK-FACTORS; HEMATOLOGIC MALIGNANCIES; HEMORRHAGIC CYSTITIS; ACUTE-LEUKEMIA; BACTEREMIA; OUTCOMES; DONORS; ADULTS;
D O I
10.1038/s41409-021-01328-4
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in 11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM was 3 months (range 1-30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years, lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM (51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
引用
收藏
页码:2432 / 2444
页数:13
相关论文
共 50 条
  • [21] Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)
    Fayard, Amandine
    Daguenet, Elisabeth
    Blaise, Didier
    Chevallier, Patrice
    Labussiere, Helene
    Berceanu, Ana
    Yakoub-Agha, Ibrahim
    Socie, Gerard
    Charbonnier, Amandine
    Suarez, Felipe
    Huynh, Anne
    Mercier, Melanie
    Bulabois, Claude-Eric
    Lioure, Bruno
    Chantepie, Sylvain
    Beguin, Yves
    Bourhis, Jean-Henri
    Malfuson, Jean-Valere
    Clement, Laurence
    de la Tour, Regis Peffault
    Cornillon, Jerome
    BONE MARROW TRANSPLANTATION, 2019, 54 (10) : 1586 - 1594
  • [22] Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide
    Mariotti, Jacopo
    De Philippis, Chiara
    Bramanti, Stefania
    Sarina, Barbara
    Tordato, Federica
    Pocaterra, Daria
    Casari, Erminia
    Carlo-Stella, Carmelo
    Santoro, Armando
    Castagna, Luca
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (04) : 357 - 367
  • [23] Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation
    Mulroney, Carolyn M.
    Bilal Abid, Muhammad
    Bashey, Asad
    Chemaly, Roy F.
    Ciurea, Stefan O.
    Chen, Min
    Dandoy, Christopher E.
    Diaz Perez, Miguel A.
    Friend, Brian D.
    Fuchs, Ephraim
    Ganguly, Siddhartha
    Goldsmith, Scott R.
    Kanakry, Christopher G.
    Kim, Soyoung
    Komanduri, Krishna V.
    Krem, Maxwell M.
    Lazarus, Hillard M.
    Ljungman, Per
    Maziarz, Richard
    Nishihori, Taiga
    Patel, Sagar S.
    Perales, Miguel-Angel
    Romee, Rizwan
    Singh, Anurag K.
    Reid Wingard, John
    Yared, Jean
    Riches, Marcie
    Taplitz, Randy
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 145 - 157
  • [24] Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease
    Harada, Kaito
    Kanda, Junya
    Hirayama, Masahiro
    Wada, Fumiya
    Uchida, Naoyuki
    Tanaka, Masatsugu
    Nakamae, Hirohisa
    Tokunaga, Masahito
    Ishiwata, Kazuya
    Onizuka, Makoto
    Hasegawa, Yuta
    Fukuda, Takahiro
    Eto, Tetsuya
    Kurita, Naoki
    Kawakita, Toshiro
    Jinguji, Atsushi
    Ishimaru, Fumihiko
    Atsuta, Yoshiko
    Nakasone, Hideki
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (02): : 103e1 - 103e13
  • [25] Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML
    Rashidi, A.
    Slade, M.
    DiPersio, J. F.
    Westervelt, P.
    Vij, R.
    Romee, R.
    BONE MARROW TRANSPLANTATION, 2016, 51 (12) : 1561 - 1564
  • [26] Successful Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in a Severe Combined Immune Deficiency Patient: a First Report
    Ouederni, Monia
    Mellouli, Fethi
    Ben Khaled, Monia
    Kaabi, Houda
    Picard, Capucine
    Bejaoui, Mohamed
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (05) : 437 - 440
  • [27] CD3+graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide
    Mussetti, A.
    De Philippis, C.
    Carniti, C.
    Bastos-Oreiro, M.
    Gayoso, J.
    Cieri, N.
    Pennisi, M.
    Ciceri, F.
    Greco, R.
    Peccatori, J.
    Patriarca, F.
    Mariotti, J.
    Castagna, L.
    Corradini, P.
    BONE MARROW TRANSPLANTATION, 2018, 53 (12) : 1522 - 1531
  • [28] HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis
    Shike, Hiroko
    Zhang, Aiwen
    CELLS, 2024, 13 (24)
  • [29] Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide
    Jaiswal, Sarita Rani
    Chakrabarti, Aditi
    Chatterjee, Sumita
    Bhargava, Sneh
    Ray, Kunal
    Chakrabarti, Suparno
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (02) : 234 - 242
  • [30] Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients
    Granata, Angela
    Furst, Sabine
    Bramanti, Stefania
    Legrand, Faezeh
    Sarina, Barbara
    Harbi, Samia
    De Philippis, Chiara
    Faucher, Catherine
    Chabannon, Christian
    Lemarie, Claude
    Calmels, Boris
    Mariotti, Jacopo
    Maisano, Valerio
    Weiller, Pierre-Jean
    Mokart, Djamel
    Vey, Norbert
    Bouabdallah, Reda
    Castagna, Luca
    Blaise, Didier
    Devillier, Raynier
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1730 - 1737